DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Pipe SW, Shima M, Lehle M. , et al.
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Lancet Haematol 2019;
6 (06) e295-e305
We do not assume any responsibility for the contents of the web pages of other providers.